The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Simple item page
dc.contributor.authorAkpinar, S
dc.contributor.authorDogu, MH
dc.contributor.authorCelik, S
dc.contributor.authorEkinci, O
dc.contributor.authorHindilerden, IY
dc.contributor.authorDal, MS
dc.contributor.authorDavulcu, EA
dc.contributor.authorTekinalp, A
dc.contributor.authorHindilerden, F
dc.contributor.authorOzcan, BG
dc.contributor.authorHacibekiroglu, T
dc.contributor.authorErkurt, MA
dc.contributor.authorBagci, M
dc.contributor.authorNamdaroglu, S
dc.contributor.authorKorkmaz, G
dc.contributor.authorBilgir, O
dc.contributor.authorCagliyan, GA
dc.contributor.authorOzturk, HBA
dc.contributor.authorSerin, I
dc.contributor.authorTiryaki, TO
dc.contributor.authorOzatli, D
dc.contributor.authorKorkmaz, S
dc.contributor.authorUlas, T
dc.contributor.authorEser, B
dc.contributor.authorTurgut, B
dc.contributor.authorAltuntas, F
dc.date.accessioned2024-07-18T12:08:14Z
dc.date.available2024-07-18T12:08:14Z
dc.description.abstractWe evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the par ticipating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+ /p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were >= grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atr ial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare dur ing the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (C) 2021 Elsevier Inc. All rights reserved.
dc.identifier.issn2152-2650
dc.identifier.other2152-2669
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10866
dc.language.isoEnglish
dc.publisherCIG MEDIA GROUP, LP
dc.subjectCHRONIC LYMPHOCYTIC-LEUKEMIA
dc.titleThe Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu